AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16625522 — intervention group
Group type: EXPERIMENTAL
Intervention: etifoxine (50 mg tid)
Number of subjects: 191
Study 16625522 — intervention group
Group type: COMPARATOR
Intervention: lorazepam (0.5-0.5-1 mg/day)
Number of subjects: 191
Study 12743558 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate for 6 weeks
Number of subjects: 28
Study 11783280 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiakang Ning (JKN) capsule
Number of subjects: 85
Study 11783280 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiakang Ning (JKN) with low dose Tapazol
Number of subjects: 85
Study 11783280 — intervention group
Group type: COMPARATOR
Intervention: Tapazol control group
Number of subjects: 85
Study 9101871 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral L‐alanyl‐L‐glutamine dipeptide
Number of subjects: 0
Study 9101871 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving parenteral glutamine)
Number of subjects: 0
Study 1929726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadiazine (or sulfisoxazole) and spiramycine
Number of subjects: 52
Study 1929726 — intervention group
Group type: COMPARATOR
Intervention: Spiramycine alone
Number of subjects: 52
Study 6293834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacmecillinam 100 mg
Number of subjects: 0
Study 6293834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacmecillinam 200 mg
Number of subjects: 0
Study 6293834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacmecillinam 400 mg
Number of subjects: 0
Study 6293834 — intervention group
Group type: COMPARATOR
Intervention: Pivmecillinam 400 mg
Number of subjects: 0
Study 6293834 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Bacmecillinam 400 mg vs Pivmecillinam 400 mg
Number of subjects: 0
Study 6293834 — intervention group
Group type: COMPARATOR
Intervention: Bacmecillinam vs Pivmecillinam
Number of subjects: 0
Study 30859975 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400mg (AOM 400) administered every 4 weeks for up to 52 weeks
Number of subjects: 464
Study 30859975 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400mg (AOM 400)
Number of subjects: 464
Study 30282798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg (days 1-21), cyclophosphamide 300 mg (days 1, 8, 15, and 22), dexamethasone 40 mg (days 1-4 and days 15-18 of a 28-day cycle) for 4 cycles (PCD)
Number of subjects: 97
Study 30282798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide-dexamethasone maintenance until disease progression
Number of subjects: 97
Study 27430319 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management course (6 weeks duration, includes education, discussions, exchange of experiences, and physical movement exercises)
Number of subjects: 120
Study 27430319 — intervention group
Group type: COMPARATOR
Intervention: Drop-in outdoor physical activity (control group)
Number of subjects: 120
Study 24281275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine continuous infusion
Number of subjects: 40
Study 24281275 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline continuous infusion (Control)
Number of subjects: 40
Study 22706931 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, web-based handover application
Number of subjects: 241
Study 20434048 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video program, one-on-one counseling, and stroke education materials
Number of subjects: 329
Study 20434048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 329
Study 18334909 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/d
Number of subjects: 593
Study 18334909 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 160 mg/d
Number of subjects: 593
Study 18334909 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/d and Ziprasidone 160 mg/d
Number of subjects: 593
Study 15704615 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine (Test)
Number of subjects: 49
Study 15704615 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole MUPS 40 mg tablets without hard gelatine capsule (Reference)
Number of subjects: 49
Study 14614229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH
Number of subjects: 198
Study 14614229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH
Number of subjects: 198
Study 10417491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation (2 mg of aerosol)
Number of subjects: 9
Study 10417491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuliser solution only (20 mg)
Number of subjects: 9
Study 10417491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuliser solution plus isotonic saline (20 mg)
Number of subjects: 9
Study 10417491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuliser solution plus saline and procaterol (20 mg)
Number of subjects: 9
Study 8853774 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (4 g daily for 12 months)
Number of subjects: 10
Study 8853774 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin capsules (placebo)
Number of subjects: 10
Study 1346877 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH treatment (4 doses of 400 micrograms 8‐hourly)
Number of subjects: 103
Study 1346877 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 103
Study 1346877 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone plus placebo (control)
Number of subjects: 103
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg
Number of subjects: 10
Study 6140699 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam 5 mg + Placebo (Ethanol 0.1 g/kg)
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg + Ethanol 0.2 g/kg
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg + Ethanol 0.4 g/kg
Number of subjects: 10
Study 6140699 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg + Placebo (Ethanol 0.1 g/kg)
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg + Ethanol 0.2 g/kg
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg + Ethanol 0.4 g/kg
Number of subjects: 10
Study 6140699 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 10
Study 6140699 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 10
Study 31092643 — intervention group
Group type: EXPERIMENTAL
Intervention: MyHeartMate app intervention
Number of subjects: 394
Study 31092643 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 394
Study 29467465 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary total knee replacement (TKR) surgery
Number of subjects: 2244
Study 27600257 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% topical gel
Number of subjects: 20
Study 27600257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25246421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-fried Mars bar
Number of subjects: 24
Study 25246421 — intervention group
Group type: COMPARATOR
Intervention: Porridge (control)
Number of subjects: 24
Study 22808165 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 99
Study 22808165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 20542800 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 46
Study 20542800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 46
Study 20542800 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 46
Study 20542800 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 46
Study 18844012 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReStor MIOL
Number of subjects: 60
Study 18844012 — intervention group
Group type: COMPARATOR
Intervention: Single focal intraocular lens (SIOL)
Number of subjects: 60
Study 15905672 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 90
Study 15905672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 90
Study 15905672 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 90
Study 12021827 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg orally once daily for 6 weeks
Number of subjects: 0
Study 12021827 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline continued for a second 6-week period
Number of subjects: 0
Study 12021827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9892879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4 or 8 weeks
Number of subjects: 202
Study 9892879 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4 or 8 weeks
Number of subjects: 202
Study 7707258 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0
Study 7707258 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 0
Study 3374808 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 0
Study 3374808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg of starch)
Number of subjects: 0
Study 29278278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 29278278 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 0.0625 mg
Number of subjects: 559
Study 29278278 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 0.125 mg
Number of subjects: 559
Study 29278278 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 0.25 mg
Number of subjects: 559
Study 29278278 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 0.5 mg
Number of subjects: 559
Study 27367422 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Based Training (CBT) of the modified Fones technique
Number of subjects: 93
Study 27367422 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Based Training (CBT) of the modified Bass technique
Number of subjects: 93
Study 27367422 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with no further instructions
Number of subjects: 93
Study 24901956 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized care (PC)
Number of subjects: 81
Study 24901956 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study 22245919 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish national return-to-work program (RTW)
Number of subjects: 19500
Study 20630890 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 60% with remifentanil
Number of subjects: 60
Study 20630890 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 2.0% with remifentanil
Number of subjects: 60
Study 20630890 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 60%
Number of subjects: 60
Study 20630890 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 2.0%
Number of subjects: 60
Study 17596905 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 268
Study 17596905 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 268
Study 17596905 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone or Methadone
Number of subjects: 268
Study 15839590 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) + bioactive glass (BG)
Number of subjects: 6
Study 15839590 — intervention group
Group type: COMPARATOR
Intervention: Bioactive glass (BG) alone
Number of subjects: 6
Study 12417358 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 12417358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10616013 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 52
Study 10616013 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day)
Number of subjects: 52
Study 9026280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GnRH agonist
Number of subjects: 2
Study 9026280 — intervention group
Group type: COMPARATOR
Intervention: Long protocol with GnRH agonist in depot formula
Number of subjects: 2
Study 2055292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 20
Study 2055292 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 20
Study 6667808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg
Number of subjects: 0
Study 6667808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg
Number of subjects: 0
Study 6667808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 150 mg
Number of subjects: 0
Study 6667808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30817764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned, frequency-modulated oral stimulation via the NTrainer system through a pulsatile pacifier
Number of subjects: 210
Study 30817764 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile pacifier
Number of subjects: 210
Study 28572492 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 8
Study 28572492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 28572492 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 27020655 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H. pylori
Number of subjects: 809
Study 27020655 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 809
Study 27020655 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H. pylori followed by celecoxib
Number of subjects: 809
Study 27020655 — intervention group
Group type: EXPERIMENTAL
Intervention: subjects with decreased COX‐2 methylation levels
Number of subjects: 809
Study 24697925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 45
Study 24697925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 45
Study 24697925 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous/oral placebo)
Number of subjects: 45
Study 23067089 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 40
Study 23067089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 40
Study 19348540 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectations
Number of subjects: 0
Study 19348540 — intervention group
Group type: COMPARATOR
Intervention: Positive expectations
Number of subjects: 0
Study 19348540 — intervention group
Group type: EXPERIMENTAL
Intervention: Event occurrence
Number of subjects: 0
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-20
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-10
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-20 (imagining movements of affected limbs)
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-20 (imagining movements of unaffected limbs)
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-10 (imagining movement of dominant limbs)
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-10 (imagining movement of nondominant limbs)
Number of subjects: 65
Study 17419886 — intervention group
Group type: EXPERIMENTAL
Intervention: KVIQ-20 and KVIQ-10
Number of subjects: 65
Study 14997006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra therapy
Number of subjects: 1007
Study 14997006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study 12352776 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week Arthritis Foundation aquatic exercise program (n = 125)
Number of subjects: 249
Study 12352776 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 124)
Number of subjects: 249
Study 9828849 — intervention group
Group type: EXPERIMENTAL
Intervention: auto-CPAP treatment
Number of subjects: 16
Study 9828849 — intervention group
Group type: COMPARATOR
Intervention: conventional CPAP treatment
Number of subjects: 16
Study 7536205 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 11
Study 2263585 — intervention group
Group type: EXPERIMENTAL
Intervention: Free running group
Number of subjects: 36
Study 2263585 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming group
Number of subjects: 36
Study 2263585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 6210722 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI), mean maximum daily dose 283 mg (range 100-400 mg/d)
Number of subjects: 34
Study 6210722 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (CMI)
Number of subjects: 34
Study 6210722 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 34
Study 31707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 436
Study 31707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg once daily)
Number of subjects: 436
Study 30321602 — intervention group
Group type: EXPERIMENTAL
Intervention: PFJ OA participants
Number of subjects: 64
Study 28153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg (4000 IU) by subcutaneous injection daily from recruitment until 36+0 weeks or delivery
Number of subjects: 156
Study 28153659 — intervention group
Group type: COMPARATOR
Intervention: Standard high-risk care only
Number of subjects: 156
Study 28153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 156
Study 25305357 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal polypropylene mesh insertion
Number of subjects: 100
Study 25305357 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 100
Study 25512817 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic testing group
Number of subjects: 60
Study 25512817 — intervention group
Group type: COMPARATOR
Intervention: Office evaluation only group
Number of subjects: 60
Study 22784845 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3 daily for 6 months
Number of subjects: 105
Study 22784845 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D3 daily for 6 months
Number of subjects: 105
Study 18979150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks plus MTX placebo
Number of subjects: 125
Study 18979150 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab placebo plus MTX 8 mg/week
Number of subjects: 125
Study 16798061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol during radiotherapy
Number of subjects: 43
Study 16798061 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (control group)
Number of subjects: 43
Study 15357025 — intervention group
Group type: EXPERIMENTAL
Intervention: MML (sn-1(3),2) fat load
Number of subjects: 10
Study 15357025 — intervention group
Group type: COMPARATOR
Intervention: MLM (sn-1,3) fat load
Number of subjects: 10
Study 15357025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fat loads
Number of subjects: 10
Study 11603877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer education program for clergy
Number of subjects: 0
Study 11603877 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9689271 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.6-0.8 vol%
Number of subjects: 556
Study 9689271 — intervention group
Group type: COMPARATOR
Intervention: Halothane 0.4-0.6 vol%
Number of subjects: 556
Study 9689271 — intervention group
Group type: COMPARATOR
Intervention: Enflurane 0.8-1 vol%
Number of subjects: 556
Study 7806832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of i.m. recombinant IFN‐alpha 2a three times per week for 3 months (group A)
Number of subjects: 62
Study 7806832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of i.m. recombinant IFN‐alpha 2a three times per week for 6 months (group B)
Number of subjects: 62
Study 2691694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 2691694 — intervention group
Group type: COMPARATOR
Intervention: Control (no antihypertensive treatment)
Number of subjects: 0
Study 1190102 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 2 g of vitamin C
Number of subjects: 0
Study 1190102 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31127479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin and carboplatin (PLDC)
Number of subjects: 100
Study 31127479 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (GC)
Number of subjects: 100
Study 31127479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 100
Study 31127479 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 100
Study 29927558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,800 IU/d supplementation for 6 weeks
Number of subjects: 76
Study 29927558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26213879 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic administration with massage
Number of subjects: 25
Study 26213879 — intervention group
Group type: COMPARATOR
Intervention: Analgesic administration alone
Number of subjects: 25